Polypharmacy and drug interactions in the management of rheumatoid arthritis
Polypharmacy is highly prevalent in rheumatoid arthritis treatment, particularly in patients with comorbidities, increasing the risk of clinically significant drug-to-drug interactions. Physicians should remain vigilant in monitoring for potential interactions and adopt strategies to mitigate the risks, such as regular medication reviews and utilizing digital platforms to support clinical decision-making. This approach is critical to optimizing patient safety and treatment outcomes in rheumatoid arthritis care.
Authors
- Natalie Sbalqueiro Fogaça (ORCID: https://orcid.org/0000-0001-8885-3718)
- Bárbara Stadler Kahlow (ORCID: https://orcid.org/0000-0001-5292-2777)
- Thelma Larocca Skare (ORCID: https://orcid.org/0000-0002-7699-3542)
- Renato Nisihara (ORCID: https://orcid.org/0000-0002-1234-8093)
- Lorena Batista Boeing (ORCID: https://orcid.org/0009-0005-4319-222X)
Institutions
- Universidade Presbiteriana Mackenzie (BR)
- Hospital Universitário Evangélico de Curitiba (BR)
- Faculdade Evangélica do Paraná (BR)
Publication Details
- Journal
- Revista da Associação Médica Brasileira
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1590/1806-9282.20250151
- Citations
- 1
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.67